XTLB on Nasdaq

XTL Bio

XTL Bio is a Clinical stage biopharmaceutical company based in Herzliya, founded in 1993.¹ Its shares trade on Nasdaq under the symbol XTLB.¹

Price unavailable

Last updated Oct 21, 2026.

Overview

1993Founded¹

Compare with Scienture Holdings, Inc., Pasithea Therapeutics Corp. or MEDICINOVA INC, or pick any stock.

TickerXTLB on Nasdaq¹
Industrybiopharmaceutical¹
HeadquartersRa'anana¹
Founded inIsrael¹
Websitewww.xtlbio.com
Legal formlimited company, public company¹
Listed onNasdaq (XTLB), Tel Aviv Stock Exchange (XTLB)¹
Incorporated inIsrael⁴
Business addressXtl Biopharmaceuticals Ltd, C/O Alston & Bird Llp, 90 Park Avenue, New York, Ny 10016⁴
Filer categoryNon-accelerated filer⁴
LEI529900NDDXEAPTUTXP41³
StatusActive³
LEI statusLapsed (not renewed)³
Registered address5 HaCharoshet St., 4365603 Raanana, Israel³
Registered withIsraeli Corporations Authority (Department of Justice), 520039470³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

0.7%Gross margin⁵

-481.6%Operating margin⁵

-227.7%Net margin⁵

-18.9%Return on equity⁵

-$1.7MFree cash flow⁵

Where the money goes

Where each dollar of revenue went, fiscal 2024

Cost of revenueResearch and developmentIncome tax

Cost of revenue64¢$448.0K
Research and development14¢$98.0K
Interest4¢$28.0K
Income tax18¢$130.0K

Out of $451.0K in revenue.⁵ The company lost money this year.

Financial statements

Operating income⁶⁷⁸⁵-$2.2M in 2024+174% since 2018

Net income⁶⁷⁸⁵-$1.0M in 2024

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Research and development expenses	-$28.0K	-$16.0K	-$31.0K
General and administrative expenses	-$1.4M	-$759.0K	-$734.0K
Other expenses	-$223.0K
Operating loss	-$1.7M	-$775.0K	-$765.0K
Change in fair value of financial instruments	$1.1M	$926.0K
Change in fair value of marketable securities	$5.0K	$167.0K	-$1.0M
Change in fair value of convertible loan from shareholder	-$54.0K
Interest expenses	-$7.0K
Other finance income	$60.0K	$34.0K	$41.0K
Other finance expenses	-$177.0K	-$112.0K	-$36.0K
Finance income (expenses), net	$929.0K	$1.0M	-$1.0M
Loss before income taxes	-$759.0K	$240.0K	-$1.8M
Profit (loss) from continuing operations	-$759.0K	$240.0K	-$1.8M
Loss from discontinued operations, net of tax	-$6.2M	-$1.3M
Net loss for the year	-$7.0M	-$1.0M	-$1.8M
Profit (loss) from continuing operations (in Dollars per share)	-$0.00	$0.00	-$0.00
Diluted profit (loss) from continuing operations (in Dollars per share)	-$0.00	$0.00	-$0.00
Loss from discontinued operations (in Dollars per share)	-$0.01	-$0.00
Diluted loss from discontinued operations (in Dollars per share)	-$0.01	-$0.00
Total basic and diluted loss per share (in Dollars per share)	-$0.01	-$0.00	-$0.00
Total diluted loss per share (in Dollars per share)	-$0.01	-$0.00	-$0.00
Weighted average number of issued ordinary shares (in Shares)	896.2M shares	673.0M shares	544.9M shares
Diluted weighted average number of ordinary shares (in Shares)	896.2M shares	673.0M shares	544.9M shares

Total assets¹⁰⁶⁷⁸⁵$8.6M in 2024−0% since 2018

Shareholders’ equity⁷⁸⁵$5.4M in 2024−25% since 2018

Cash⁷⁸⁵$371.0K in 2024−89% since 2018

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 7 quarters (quarterly), latest first.⁹

Period ending	2025-12-31	2025-09-30	2024-12-31	2024-09-30	2024-07-31
Cash and cash equivalents	$76.0K		$371.0K
Marketable securities InterCure Ltd.			$772.0K
Trade receivable (net of allowance for credit losses of $0 and $36 at December 31, 2025 and 2024, respectively)			$99.0K
Prepaid expenses and other current assets	$22.0K		$98.0K
Warrants, net	$68.0K
Total current assets	$166.0K		$1.3M
Fixed assets, net			$187.0K		$167.0K
Intangible assets, net			$3.8M		$3.6M
Goodwill			$3.2M		$3.2M
Long-term bank deposit			$14.0K
Total Non-current assets			$7.2M
Total assets	$166.0K		$8.6M		$5.8M
Loans and credit from banking corporations			$138.0K	$163.0K
Accounts payable	$151.0K		$790.0K
Warrants, net			$1.3M
Convertible loan from shareholder	$269.0K
Total current liabilities	$420.0K		$2.2M
Warrants			$689.0K
Deferred tax liability, net			$219.0K
Total Non-Current liabilities			$908.0K
Share capital - ordinary shares of NIS 0.1 par value: Authorized December 31, 2025 and 2024 - 1,450,000,000; Issued and outstanding - 946,243,356 on December 31, 2025 and 881,385,256 on December 31, 2024;	$25.1M		$23.1M
Additional paid in capital	$140.2M	$1.1M	$141.3M
Reserve from transactions with non-controlling interests	$20.0K		$20.0K
Accumulated deficit	-$165.6M		-$159.0M
Total equity	-$254.0K		$5.4M
Total liabilities and equity	$166.0K		$8.6M
Trade receivable net of allowance for credit losses	$0		$36.0K
Ordinary shares, par value (in New Shekels per share)	0.10 ILS		0.10 ILS
Ordinary shares, shares authorized (in Shares)	1.4B shares		1.4B shares
Ordinary shares, shares issued (in Shares)	946.2M shares		881.4M shares
Ordinary shares, shares outstanding (in Shares)	946.2M shares		881.4M shares

Period ending	2025-12-31	2025-09-30	2024-12-31	2024-09-30	2024-07-31	2023-12-31	2022-12-31
Cash and cash equivalents	$76.0K		$371.0K			$1.4M	$2.1M
Marketable securities InterCure Ltd.			$772.0K			$605.0K	$1.6M
Trade receivable (net of allowance for credit losses of $0 and $36 at December 31, 2025 and 2024, respectively)			$99.0K
Prepaid expenses and other current assets	$22.0K		$98.0K
Warrants, net	$68.0K
Total current assets	$166.0K		$1.3M
Fixed assets, net			$187.0K		$167.0K
Intangible assets, net			$3.8M		$3.6M
Goodwill			$3.2M		$3.2M
Long-term bank deposit			$14.0K
Total Non-current assets			$7.2M
Total assets	$166.0K		$8.6M		$5.8M
Loans and credit from banking corporations			$138.0K	$163.0K
Accounts payable	$151.0K		$790.0K
Warrants, net			$1.3M
Convertible loan from shareholder	$269.0K
Total current liabilities	$420.0K		$2.2M
Warrants			$689.0K
Deferred tax liability, net			$219.0K
Total Non-Current liabilities			$908.0K
Share capital - ordinary shares of NIS 0.1 par value: Authorized December 31, 2025 and 2024 - 1,450,000,000; Issued and outstanding - 946,243,356 on December 31, 2025 and 881,385,256 on December 31, 2024;	$25.1M		$23.1M
Additional paid in capital	$140.2M	$1.1M	$141.3M
Reserve from transactions with non-controlling interests	$20.0K		$20.0K
Accumulated deficit	-$165.6M		-$159.0M
Total equity	-$254.0K		$5.4M			$2.2M	$4.0M
Total liabilities and equity	$166.0K		$8.6M
Trade receivable net of allowance for credit losses	$0		$36.0K
Ordinary shares, par value (in New Shekels per share)	0.10 ILS		0.10 ILS
Ordinary shares, shares authorized (in Shares)	1.4B shares		1.4B shares
Ordinary shares, shares issued (in Shares)	946.2M shares		881.4M shares
Ordinary shares, shares outstanding (in Shares)	946.2M shares		881.4M shares

Cash from operations⁶⁷⁸⁵-$1.6M in 2024+98% since 2018

Capital spending⁷⁸⁵$54.0K in 2024+2600% since 2019

Free cash flow⁷⁸⁵-$1.7M in 2024+84% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁹

Period ending	2025-12-31	2024-12-31	2023-12-31
Net Loss for the Year	-$7.0M	-$1.0M	-$1.8M
Adjustments to reconcile net income (loss) to net cash used in operating activities (a)	$5.9M	-$591.0K	$1.1M
Net cash used in operating activities	-$1.0M	-$1.6M	-$707.0K
Purchase of fixed assets		-$54.0K
Interest from bank deposit		$34.0K	$41.0K
Investment in long-term deposits		-$14.0K
Acquisition of subsidiary, consolidated for the first time (see Note 5)		-$410.0K
Loan provided to subsidiary prior to acquisition		-$400.0K
Proceeds from sale of marketable securities	$777.0K
Loan to former subsidiary	-$250.0K
Cash and cash equivalents of deconsolidated subsidiary (see note 6)	-$5.0K
Net cash provided by (used in) investing activities	$522.0K	-$844.0K	$41.0K
Loan repayment		-$13.0K
Issuance of shares and warrants		$1.5M
Shareholder loan	$208.0K
Net cash provided by financing activities	$208.0K	$1.4M
Decrease in cash and cash equivalents	-$295.0K	-$1.0M	-$666.0K
Losses from exchange rate differences on cash and cash equivalents		-$15.0K	-$27.0K
Depreciation and amortization		$199.0K
Change in deferred taxes		-$130.0K
Revaluation of marketable securities	-$5.0K	-$167.0K	$1.0M
Revaluation of warrants	-$1.1M	-$926.0K
Share-based payment expense	$346.0K	$264.0K	$3.0K
Impairment loss on intangible assets	$223.0K
Bad debt loss	$308.0K
Exchange rate differences	-$35.0K	$14.0K	$27.0K
Interest income	-$60.0K	-$34.0K	-$41.0K
Interest expenses	$7.0K
Revaluation of convertible loan	$54.0K
Loss from disposal/deconsolidation of subsidiary	$6.2M
Net income and expenses not involving operating cash flows	$5.9M	-$780.0K	$1.0M
Decrease (increase) in prepaid expenses and other current assets	$28.0K	-$58.0K	$45.0K
Decrease in trade receivables	$157.0K	$39.0K
Increase (decrease) in accounts payable	-$187.0K	$208.0K	$19.0K
Net operating asset and liability	-$2.0K	$189.0K	$64.0K
Net cash provided by (used in) operating activities	$5.9M	-$591.0K	$1.1M

Compare XTL Bio with another company

What it owns

What XTL Bio reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$187.0K⁵ Dec 31, 2024	$10.0K¹¹ Dec 31, 2016	+1770.0%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$371.0K⁵ Dec 31, 2024	$1.4M⁵ Dec 31, 2023	−73.5%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$3.2M⁵ Dec 31, 2024
Intangible assets, net (excluding goodwill)	$3.8M⁵ Dec 31, 2024	$380.0K⁵ Dec 31, 2023	+904.2%

Leadership

Who has led XTL Bio, and when. Pick a name to see everywhere that person has worked.

Chief executive

Ron Bentsur2006–2007

1995200020052010201520202025

Chief executive officerRon Bentsur Aug 17, 2006 to Aug 21, 2007¹²

Board members and other officers (8)

Director of FinanceWilliam Kessler Aug 22, 2007 to Aug 22, 2007¹³
Board memberFain Osnat Hillel Mar 23, 2026 to now¹⁴
Board memberMichael S. Weiss Aug 26, 2008 to Nov 4, 2008¹⁵
Board memberBen-Zion Weiner Sep 4, 2008 to Nov 4, 2008¹⁶
Board memberJennifer L. Good Nov 4, 2008 to Nov 4, 2008¹⁷
Board memberKenneth J. Zuerblis Nov 4, 2008 to Nov 4, 2008¹⁸
Board memberSamuel Rudman Nov 4, 2008 to Nov 4, 2008¹⁹
Board memberWilliam James Kennedy Nov 4, 2008 to Nov 4, 2008²⁰

Timeline

Aug 17, 2006New chief executive Ron Bentsur becomes CEO¹²
1993Founded Founded in Israel¹

Filings

71 filings to the SEC since October 2021: 5 annual reports, 2 insider forms, 64 other. The latest 20:

Oct 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Jul 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Jun 30, 202620-F ANNUAL REPORT EDGAR
Jun 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Jun 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Jun 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
May 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
May 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
May 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Apr 30, 2026NT 20-F NOTIFICATION OF LATE FILING EDGAR
Apr 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Mar 23, 20263 EDGAR
Mar 23, 20263 EDGAR
Mar 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Mar 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Feb 27, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Feb 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Feb 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
Feb 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 71 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Rhumbline Advisers	6,228	$17.0K	0.0%	+241
GAMMA Investing LLC	1,213	$3.3K	0.0%	−2,175
UBS Group AG	125	$341	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How XTL Bio is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARXTL BIOPHARMACEUTICALS LTD²
CIK0001023549
Filer statusNon-accelerated filer not an emerging growth company; not a shell company²¹
Incorporated inIsrael²¹
Industry code (SIC)2834 Pharmaceutical Preparations²
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance²
Business addressXtl Biopharmaceuticals Ltd, C/O Alston & Bird Llp, 90 Park Avenue, New York, NY 10016²
Mailing address85 Medinat Ha-Yehudim St., Herzliya, 4676670, Israel²
Phone972 9 955 7080²
Shares outstanding946,243,356 shares as of Dec 31, 2025²¹
AuditorBarzily and Co. CPAs, Jerusalem, Israel PCAOB ID 1015; no auditor attestation of internal control over financial reporting²¹
On EDGAR sinceNov 17, 2004²
Filings546 in all: 6-K (380), 4 (37), 20-F (21), 3 (11), CORRESP (10), UPLOAD (9), EFFECT (7), 424B3 (6)²
All 36 form types
SC 13G/A (6), 6-K/A (5), F-3/A (5), 20-F/A (4), F-3 (4), SC 13G (4), 20FR12G/A (3), 424B5 (3), F-1/A (3), S-8 (3), S-8 POS (3), 20FR12G (2), CT ORDER (2), D (2), F-1 (2), SC 13D/A (2), 25-NSE (1), 3/A (1), 8-A12B (1), CERTNAS (1), F-6 (1), F-6EF (1), FWP (1), NT 20-F (1), POS AM (1), REGDEX (1), RW (1), SC 13D (1)
Latest filingsAnnual report (20-F) Jun 30, 2026

Securities registered for trading

Class	Symbol	Exchange
American Depositary Shares, each representing one hundred Ordinary Shares, par value NIS 0.1	XTLB	Nasdaq

From the cover page of the 20-F filed Jun 30, 2026 (Section 12(b) of the Exchange Act).²¹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataXTL Bio on Wikidata
2
SEC EDGARXTL Bio filings on SEC EDGAR
3
GLEIFXTL Bio LEI record (529900NDDXEAPTUTXP41)
4
SEC EDGARXTL Bio filings on SEC EDGAR
5
SEC EDGARXTL Bio 10-K for fiscal 2024
6
SEC EDGARXTL Bio 10-K for fiscal 2018
7
SEC EDGARXTL Bio 10-K for fiscal 2019
8
SEC EDGARXTL Bio 10-K for fiscal 2020
9
SEC EDGARXTL Bio 20-F filed 2026-06-30: income statement
10
SEC EDGARXTL Bio 10-K for fiscal 2018
11
SEC EDGARXTL Bio 20-F for fiscal 2017
12
SEC EDGARRon Bentsur, Chief executive officer
13
SEC EDGARWilliam Kessler, Director of Finance
14
SEC EDGARFain Osnat Hillel, Board member
15
SEC EDGARMichael S. Weiss, Board member
16
SEC EDGARBen-Zion Weiner, Board member
17
SEC EDGARJennifer L. Good, Board member
18
SEC EDGARKenneth J. Zuerblis, Board member
19
SEC EDGARSamuel Rudman, Board member
20
SEC EDGARWilliam James Kennedy, Board member
21
SEC EDGARXTL Bio 20-F filed Jun 30, 2026: cover page